Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain

This is the first study to investigate the acceptability of naloxone co-prescription among providers in clinics supporting the practice. Most providers actively engaged in providing naloxone, and the vast majority intended to continue to do so in the future. Providers noted education, pharmacy, and payer logistics as barriers to naloxone prescribing. Since the time of this study, two formulations of naloxone designed for lay administration (a nasal spray and an auto-injector) have been approved by the U.S. Food and Drug Administration. Unlike other naloxone devices, these new formulations require no assembly and have no additional components such as an atomizer. Additionally, the new formulations are accompanied by instructions for pharmacists. These changes should alleviate most of the concerns noted by providers in this study around education, logistics, and administration.


Abstract | Full text HTML | Full text PDF